Online Program Home
My Program

Abstract Details

Activity Number: 571 - Special Topics and Case Studies in Clinical Trials
Type: Contributed
Date/Time: Wednesday, July 31, 2019 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #307261
Title: Making an Impact: the Filing Story of ZINPLAVA
Author(s): Alison Pedley*
Keywords: Impact; Sensitivity; Filing; Interpretation

Two large (N = 400/group) double-blind, randomized, placebo-controlled, phase 3 trials were conducted to demonstrate the superiority of ZINPLAVA over placebo in patients with C. difficile infection receiving standard of care antibiotics. In both trials, the primary endpoint, recurrent infection (new episode following initial clinical cure) within 12 weeks was met as the rate of recurrent C. difficile infection was significantly lower with ZINPLAVA than with placebo (Study 1: 17% vs. 28%; P< 0.001; Study 2: 16% vs. 26%; P< 0.001). However, the rates of initial clinical cure favored placebo in Study 1 (83% vs. 77%, one-sided p = 0.032) and ZINPLAVA in Study 2 (83% vs. 78%, one-sided p-value = 0.048). Ad-hoc sensitivity analyses designed, conducted, and interpreted by the statistical team to better understand the data and the impact of clinical cure on the primary endpoint presented at the product’s advisory committee meeting proved to be critical to the product’s approval.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2019 program